We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Astex Pharmaceuticals Announces Subcutaneous SGI-110 Interim Phase 1/2 Data
News

Astex Pharmaceuticals Announces Subcutaneous SGI-110 Interim Phase 1/2 Data

Astex Pharmaceuticals Announces Subcutaneous SGI-110 Interim Phase 1/2 Data
News

Astex Pharmaceuticals Announces Subcutaneous SGI-110 Interim Phase 1/2 Data

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Astex Pharmaceuticals Announces Subcutaneous SGI-110 Interim Phase 1/2 Data"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Astex Pharmaceuticals, Inc. has announced that interim Phase 1/2 clinical data from subcutaneous SGI-110, a novel hypomethylating agent, demonstrated differentiated PK profile, good tolerability, and preliminary promising complete responses in heavily pretreated acute myelogenous leukemia (AML) patients enrolled in the Phase 1 segment of the trial.

The data was presented at an oral session at the American Association for Cancer Research (AACR) 2012 Annual Meeting in Chicago, IL and was featured in a joint AACR-Stand Up To Cancer (SU2C) media forum.

SU2C has provided funding for the Epigenetics Dream Team that is collaborating on the scientific evaluation of SGI-110.

The randomized Phase 1/2 first-in-human dose escalation study enrolled 66 patients with previously treated intermediate or high-risk myelodysplastic syndromes (MDS) or AML as of March 28, 2012.

Of seven evaluable refractory AML patients who had adequate hypomethylation with no prior resistance to hypomethylating agents (HMAs), two showed complete response, and one showed partial response.

Additionally, the pharmacokinetic (PK) data suggests delivery of decitabine by SGI-110 achieves high decitabine exposure and longer half-life than decitabine intravenous (IV) infusion.

The pharmacodynamic (PD) data shows potent dose-dependent hypomethylation induction in the daily regimen.

“This interim SGI-110 data is very encouraging for refractory AML patients,” said Jean-Pierre Issa, MD, professor of medicine and director of the Fels Institute for Cancer Research and Molecular Biology at Temple University.

Issa continued, “With the optimal biologically effective dose reached, this provides a firm basis to begin the dose expansion segment of the trial for treatment of elderly AML and previously untreated MDS.”

“This is a great example of collaboration between SU2C and industry,” said Stephen B. Baylin, MD, professor of oncology and medicine, deputy director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; co-leader of the Epigenetics Dream Team of SU2C.

Baylin continued, “The trial used a biologically driven design where dose escalation was based on biological efficacy of the drug and not just toxicities as is often the case with cancer drugs. Achieving clinical efficacy at the biologically effective doses is a validation of this innovative design."

Advertisement